SOPHiA GENETICS (SOPH) CTO trades 5,000 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA reported that Chief Technology Officer Abhimanyu Verma sold 5,000 Ordinary Shares on 2026-08-04 at a weighted average price of $6.9543 per share, in multiple trades between $6.95 and $6.98. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and Verma now holds 187,171 Ordinary Shares directly.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Verma Abhimanyu

Role Chief Technology Officer

Sold 5,000 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	5,000	$6.9543	$35K

Holdings After Transaction: Ordinary Shares — 187,171 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.95 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 Ordinary Shares Weighted average sale price: $6.9543 per share Shares owned after transaction: 187,171 Ordinary Shares +1 more

4 metrics

Shares sold 5,000 Ordinary Shares Non-derivative sale by CTO Abhimanyu Verma on 2026-08-04

Weighted average sale price $6.9543 per share Multiple transactions at prices ranging from $6.95 to $6.98 per share

Shares owned after transaction 187,171 Ordinary Shares Direct holdings of Abhimanyu Verma following the 5,000-share sale

Net shares sold 5,000 shares Net-sell direction per transaction summary for this Form 4

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: Ordinary Shares in the reported transaction."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:14 PM Accepted by SEC EDGAR 08/05/2026 - 04:14 PM Learn about SEC filing dates

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) disclose in this Form 4?

SOPHiA GENETICS disclosed that CTO Abhimanyu Verma sold 5,000 Ordinary Shares on 2026-08-04. The shares were sold at a weighted average price of $6.9543 per share in multiple trades between $6.95 and $6.98, under a Rule 10b5-1 plan.

At what prices did the SOPHiA GENETICS (SOPH) shares trade in the CTO’s sale?

The CTO’s 5,000-share sale executed at a weighted average price of $6.9543 per share. According to the disclosure, the individual trades occurred in a range of $6.95 to $6.98 per share, inclusive, across multiple transactions.

How many SOPHiA GENETICS (SOPH) shares does the CTO hold after this transaction?

Following the sale, CTO Abhimanyu Verma beneficially owns 187,171 Ordinary Shares directly. This figure represents his reported position after disposing of 5,000 shares in the 2026-08-04 transaction executed under a Rule 10b5-1 trading plan.

Was the SOPHiA GENETICS (SOPH) CTO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan. The document-level 10b5-1 checkbox is also affirmed, indicating the reported sale was pre-arranged under this type of trading plan.

Who from SOPHiA GENETICS (SOPH) executed the reported share sale and in what capacity?

The share sale was executed by Abhimanyu Verma, who serves as Chief Technology Officer of SOPHiA GENETICS SA. The Form 4 identifies him as an officer, with the transaction involving directly held Ordinary Shares of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verma Abhimanyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/04/2026		S		5,000(1)	D	$6.9543(2)	187,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.95 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)